Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Black Diamond Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -37.55%.
The industry rank for Black Diamond Therapeutics's 3-Year RORE % or its related term are showing as below:
BDTX's 3-Year RORE % is ranked worse than 74.4% of 1289
companies
in the Biotechnology industry
Industry Median: -11.44
vs BDTX: -37.55
Black Diamond Therapeutics (NAS:BDTX) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Black Diamond Therapeutics 3-Year RORE % Related Terms
Black Diamond Therapeutics 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Black Diamond Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Black Diamond Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Black Diamond Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Black Diamond Therapeutics (BDTX) has a 3-Year RORE % of -37.55 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Black Diamond Therapeutics and its competitors. According to the industry distribution chart, Black Diamond Therapeutics ranks #959 out of 1289 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Black Diamond Therapeutics' 3-Year RORE % too high?
Black Diamond Therapeutics' current 3-Year RORE % is -37.55. Based on the distribution chart, Black Diamond Therapeutics ranks #959 out of 1289 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Black Diamond Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' 3-Year RORE % compare to CGTX and PMN?
According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #959 out of 1289 companies for 3-Year RORE %. This places Black Diamond Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current 3-Year RORE % is -37.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current 3-Year RORE % of -37.55. The current 3-Year RORE % is -37.55. Black Diamond Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current 3-Year RORE % is -37.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
36GF Score
Get the complete analysis for BDTX
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDTX has been successfully added to your 
